Skip to main content
Equibles
CGTX logo

CGTX · Cognition Therapeutics Inc

Track CGTX — free

Use CGTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.03 -0.02 (-1.90%) At close · Sep 4
Rebalance outlook locked
Market Cap
$97.95M
Shares
95.09M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.03 Open$1.05 Day$1.01–1.05 52W close$0.60–2.61 Avg vol 30d490K Short int7.1M · 7.5% float · 10.1d Short vol59% Last earningsMar 26, 2026 DataOct 2021–Sep 2026 Filing10-Q · Aug 7

Up next

Latest filing: 10-Q
filed Aug 7, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$16.77M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$34.01M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+42.3%
Year over year · more shares
Price change (1Y)
-60.2%
Trailing year
Short interest
7.5%
Latest settlement · 10.1 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −14%
below
Price vs 50-day avg +1%
above
RSI (14) 51
neutral
MACD trend Positive
52-week position 22%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −5%
trailing
6-month return −5%
trailing
YTD return −24%
this year
Relative strength −20%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-12% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.49% of float · ▼ -20.2% MoM · 10.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
66 holders — mid 3-yr range
Squeeze score 61
elevated · 0–100
Fundamentals
Fair
EPS growth +63%
Y/Y
Free cash flow $-24.6M
Quant / Vol
risk profile
Very High
Volatility 105%
annualized · 1-yr
Max drawdown −77%
past year
ATR 5.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−14% Bearish
Price vs 50-day avg
+1% Bullish
RSI (14)
51 Neutral
MACD trend
Positive Bullish
52-week position
22% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-12% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.49% of float · ▼ -20.2% MoM · 10.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
66 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 22% Range high $3
vs 200-day avg -14% vs 50-day avg +1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CGTX
Cognition Therapeutics Inc
this stock
$97.95M -23.7% — — 7.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $141.42B +20.5% +46.2% 32.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.22B +7.2% +20.8% 20.5 2.3%
ARGX
Argenx SE
 $64.44B +22.9% — — 1.9%
CSLLY
Csl Ltd
 $60.55B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
66
% held
23.8%
Net QoQ
+1.2M sh
Top holder
BIOS Capital Management,…
Held Float
View
Held by Funds
Fund positions
15
View
Short & Settlement
Short Interest Falling
Shares short
7.1M
Days to cover
10.1d
Change
-1.8M sh
View
Short Volume
Short vol %
59%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
27.2K
Value
$28.3K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
55.9%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-23.5M
EPS diluted
$-0.32
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 7, 2026
This year
14
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
CGTX +1.0% -4.6% -4.6% +0.0% -23.7%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY +0.9% -4.2% -19.8% -0.4% -36.6%
Key facts CIK 1455365 CUSIP 19243B102 13F (30d) 47 filings 47 filers Visit website Investor relations